Health Economics›Follicular lymphoma›Advanced disease first-line therapy randomized data

Advanced disease first-line therapy randomized data

Follicular lymphoma · 16 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 3 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Bendamustine and Obinutuzumab Variant #02	—	R 106 233	28d	—	—	—	—	2
G-CHOP Variant #01	—	R 96 266	21d	—	—	—	—	—
G-CVP Variant #01	—	R 95 787	21d	—	—	—	—	—
Lenalidomide and Rituximab (R2) Variant #10	—	R 86 746	35d	—	—	—	—	1
R-CHOP Variant #23	—	R 59 865	21d	44.4 mo	—	65	R 3 891 219 PFS proxy	2
R-FND Variant #02	—	R 46 106	28d	—	—	—	—	—
Bendamustine and Rituximab (BR) Variant #12	—	R 40 807	28d	—	—	—	—	1
R-CHVP+I Variant #01	—	R 36 137	28d	—	—	—	—	—
R-FM Variant #01	—	R 22 297	28d	—	—	—	—	—
R-MCP Variant #01	—	R 18 304	28d	—	—	—	—	—
R-CVP Variant #01	—	R 12 182	21d	—	—	—	—	1
Rituximab and hyaluronidase monotherapy Variant #01 Partial	—	R 11 796	28d	—	—	—	—	1
Chlorambucil monotherapy Variant #12	—	R 2 523	14d	~12.6 mo	~69.7 mo	~28	~R 70 639 PFS proxy · indirect	6
Cyclophosphamide monotherapy N/A - secondary systemic drug	—	R 60	28d	—	~15.8 mo	—	—	1
Rituximab monotherapy N/A - secondary systemic drug	—	R 52	180d	~11.0 mo	—	~2	~R 104 PFS proxy · indirect	6
Watchful waiting Partial	—	—	—	~12.9 mo	—	—	—	—

16 of 16 regimens shown